Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ReNeuron Group head of research to present encouraging early data on potential cancer treatment

Dr Randolph Corteling will detail his findings at the 2018 International Society of Cell Therapy conference in Montreal
cancer cells
Has ReNeuron found a new way to tackle cancer?

ReNeuron Group Plc's (LON:RENE) shares rose on Friday after the group revealed its head of research will present exciting early-stage data on the potential use of cell-derived exomes in the treatment of cancer.  

Exosomes are nanoparticles secreted from many different types of cells and play a key role in cell-to-cell signalling.

READ: ReNeuron wins £1.5mln to fund further development of its hRPC cell therapy candidate

Early research with ExoPr0 exomes has demonstrated their potential as both a possible therapy and as a drug delivery vehicle.

Dr Randolph Corteling and his team have discovered the ExoPr0 candidate they have identified induces a process called apoptosis in cancer, which simply means cell death. It also appears to arrest cell growth.

Used in tumour models 

Using the xenograft tumour models ExoPr0 significantly reduced the mass in a number of different cancers.

When combined with the standard of care for the various growths, the ReNeuron discovery brought about an "additive reduction of tumour volume".

It should be cautioned that this is very early stage work, though nevertheless encouraging.

Corteling will deliver his findings during a podium presentation later Friday at the 2018 International Society of Cell Therapy conference in Montreal, Canada.

"We draw considerable encouragement from these new pre-clinical results and look forward to presenting further progress with the development of ExoPr0 as a potential new and highly novel cancer therapy in the months ahead," he said ahead of the gathering.

In lunchtime trading, ReNeuron shares were 3.2% higher at 62p.

 -- Adds share price --


View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use